Medical-economic Evaluation of the Care of Refractory Ascites by Implantation of Alfapump® Device in Cirrhotic Patients

Recruiting N/A Interventional Study
Ascites Paracentesis Cirrhosis
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
90 (estimated)
Sponsor
University Hospital, Grenoble · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The hypothesis is that the Alfapump® strategy would be more effective in terms of QALYs generated , and that the cost of Alfapump® device and its implantation will be totally or partially offset by the reduction in the number of evacuating parentheses performed and the reduction in the number of complications in patients with refractory ascites awaiting liver transplantation or not. On the other h…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Patient with refractory ascites who has had a minimum of 5 paracentesis in the last 3 months. * Patient with an estimated life expectancy of at least 6 months on the day of inclusion. * Patient with contraindication to the application of a TIPS or who has expressed a refusal o…
Contacts

Sandra DAVID-TCHOUDA, MD

+33 476 76 71 86

sdavidtchouda@chu-grenoble.fr

CONTACT

Sandrine MASSICOT

+33 476 76 88 60

smassicot@chu-grenoble.fr

CONTACT